Cutler Group LP Ultragenyx Pharmaceutical Inc. Call Options Transaction History

Cutler Group LP

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2023 Nov 07, 2023	BUY	$34.92 - $46.66 $73,332 - $97,986	2,100 New	2,100 $2,000
Q2 2021 Jul 19, 2021	SELL	$92.19 - $115.71 $460,950 - $578,550	-5,000 Closed	0 $0
Q1 2021 Apr 26, 2021	SELL	$106.9 - $167.73 $534,500 - $838,650	-5,000 Reduced 50.0%	5,000 $1,000
Q4 2020 Jan 21, 2021	BUY	$84.4 - $177.39 $675,200 - $1.42 Million	8,000 Added 400.0%	10,000 $37,000
Q2 2018 Aug 10, 2018	BUY	$48.54 - $85.31 $48,540 - $85,310	1,000 Added 100.0%	2,000 $54,000
Q1 2018 May 11, 2018	BUY	$44.33 - $58.52 $39,897 - $52,668	900 Added 900.0%	1,000 $1,000
Q4 2017 Jan 17, 2018	SELL	$43.54 - $57.32 $496,356 - $653,448	-11,400 Reduced 99.13%	100 $0
Q3 2017 Oct 17, 2017	BUY	$49.79 - $66.32 $572,585 - $762,679	11,500	11,500 $3,000

325

85.5M

520K

406K

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.14B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.